Comparative Pharmacology
Head-to-head clinical analysis: DIMETANE versus DRIXORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMETANE versus DRIXORAL.
DIMETANE vs DRIXORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimetane (brompheniramine) is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also has anticholinergic and sedative properties.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
1-2 tablets (4-8 mg chlorpheniramine maleate) orally every 4-6 hours, not to exceed 12 tablets (48 mg) in 24 hours.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in adults, necessitating twice-daily or three-times-daily dosing for continuous effect.
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Primarily renal excretion of metabolites, with approximately 50% of a dose excreted in urine as unchanged drug and metabolites; biliary/fecal excretion is minor (< 10%).
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Category C
Category C
Antihistamine
Antihistamine/Decongestant